CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenienceFDA removal of the prior drug exposure limit provides greater dosing flexibility infuture clinical trialsCervoMed plans to advance a 100 mg twice-daily regimen expected to a…